Show simple item record

dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorRojas Puentes, Leonardo
dc.contributor.authorWills, Beatriz
dc.contributor.authorArrieta, Oscar
dc.contributor.authorCarranza Isaza, Hernán
dc.contributor.authorVargas Báez, Carlos Alberto
dc.contributor.authorOtero, Jorge
dc.contributor.authorCorrales-Rodriguez, Luis
dc.contributor.authorMartín, Claudio
dc.contributor.authorReguart, Noemi
dc.contributor.authorArchila, Pilar
dc.contributor.authorRodríguez Ariza, July Katherine
dc.contributor.authorCuello, Mauricio
dc.contributor.authorOrtíz, Carlos
dc.contributor.authorFranco, Sandra
dc.contributor.authorRolfo, Christian
dc.contributor.authorRosell, Rafael
dc.publisherImpact Journalsspa
dc.relation.ispartofseriesOncotarget, 1949-2553. Vol, 7, Nro, 42.
dc.rightsAttribution 4.0 International*
dc.titleBIM deletion polymorphisms in hispanic patients with non-small cell lung cancer carriers of EGFR mutationsspa
dc.subject.decsNeoplasias pulmonaresspa
dc.subject.decsProteína 11 similar a Bcl2spa
dc.subject.decsGenes erbB-1spa
dc.subject.keywordsBIM deletionspa
dc.subject.keywordsNon-small cell lung cancerspa
dc.subject.keywordsEGFR mutationspa
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.contributor.orcidCarranza Isaza, Hernán [0000-0002-3593-7405]
dc.contributor.orcidVargas Báez, Carlos Alberto [0000-0002-6076-8260]
dc.contributor.orcidRojas Puentes, Leonardo [0000-0002-7865-5424]
dc.contributor.orcidRodríguez Ariza, July Katherine [0000-0003-1168-595X]
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame: Repositorio Institucional Universidad El Bosquespa
dc.title.translatedBIM deletion polymorphisms in hispanic patients with non-small cell lung cancer carriers of EGFR mutations
dc.description.abstractenglishBackground: Germline alterations in the proapoptotic protein Bcl-2-like 11 (BIM) can have a crucial role in diverse tumors. To determine the clinical utility of detecting BIM deletion polymorphisms (par4226 bp/ par363 bp) in EGFR positive non-small-cell lung cancer (NSCLC) we examined the outcomes of patients with and without BIM alterations. Results: BIM deletion was present in 14 patients (15.7%). There were no significant differences between patients with and without BIM-del in clinical characteristics or EGFR mutation type; however, those with BIM-del had a worse overall response rate (ORR) to erlotinib (42.9% vs. 73.3% in patients without BIM-del; p=0.024) as well as a significantly shorter progression-free survival (PFS) (10.8 BIM-del+ vs. 21.7 months for patients without BIM-del; p=0.029) and overall survival (OS) (15.5 BIM-del+ vs. 34.0 months for patients without BIM-del; p=0.035). Multivariate Cox regression analysis showed that BIM-del+ was an independent indicator of shorter PFS (HR 3.0; 95%CI 1.2-7.6; p=0.01) and OS (HR 3.4; 95%CI 1.4-8.3; p=0.006). Methods: We studied 89 NSCLC Hispanic patients with EGFR mutation who were treated with erlotinib between January 2009 and November 2014. BIM deletion polymorphisms (BIM-del) was analyzed by PCR in formalin-fixed paraffin-embedded (FFPE) tissues of tumor biopsies. We retrospectively analyzed clinical characteristics, response rate, toxicity, and outcomes among patients with and without BIM-del. Conclusions: The incidence of BIM-del found in Hispanic patients is similar to that previously described in Asia. This alteration is associated with a poor clinical response to erlotinib and represents an independent prognostic factor for patients who had NSCLC with an EGFR
dc.rights.localAcceso abiertospa

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International